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Toxoplasmosis remains a world-threatening disease largely because of the lack of a fully 
effective vaccine. Here, we created a ΔGRA17 mutant by disrupting the virulence factor 
GRA17 using CRISPR-Cas9 method. Then, we tested whether ΔGRA17 tachyzoites can 
be used as a live-attenuated vaccine against acute, chronic, and congenital Toxoplasma 
gondii infection in mice. Immune response evoked by ΔGRA17 immunization suggested a 
sequential Th1 and Th2 T cell response, indicated by high levels of Th1 and a mixed Th1/
Th2 cytokines at 28 and 70 days after immunization, respectively. ΔGRA17-mediated 
immunity fully protected mice against lethal infection with wild-type (wt) RH strain, het-
erologous challenge with PYS, and TgC7 strains of the Chinese ToxoDB#9 genotype, 
and T. gondii Pru strain. Although parasite cysts were detected in 8 out of 10 immunized 
mice, cyst burden in the brain was significantly reduced (P < 0.05) in immunized mice 
(53 ± 15 cysts/brain) compared to non-immunized mice (4,296 ± 687 cysts/brain). In 
respect to congenital infection, the litter size, survival rate, and body weight (BW) of 
pups born to ΔGRA17-immunized dams were not different compared to pups born to 
naïve control dams (P = 0.24). However, a marked reduction in the litter size (P < 0.001), 
survival rate, and BW (P < 0.01) of pups born to non-immunized and infected dams 
was detected. Also, immunized dams infected with type II Pru strain had significantly 
(P < 0.001) less cyst burden in the brain compared with non-immunized and infected 
dams. These findings show that immunization with ΔGRA17 strain evokes cell-mediated 
and neutralizing antibody responses and confers some degree of protection against 
challenge with homologous and heterologous virulent T. gondii strains.
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inTrODUcTiOn
The obligate intracellular apicomplexan protozoan Toxoplasma gondii is capable of infecting 
almost virtually all warm-blooded animals and has been estimated to chronically infect one-
third of the world’s population (1). Infection of humans and animals (intermediate host) occurs 
by ingestion of either tissue cysts (containing bradyzoites) in undercooked meat or oocysts 
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(containing sporozoites) that are shed in the feces of cat (defini-
tive host). The pathogenesis of T. gondii infection consists of 
a primary infection at the site of exposure, transport of the 
parasite into many body organs especially the nervous system 
where acute and latent infection develop. T. gondii infection 
is often asymptomatic in immunocompetent individuals; 
however, the parasite can cause serious health consequences 
in immunocompromised individuals, such as AIDS patients 
(2–4). Primary or reactivated toxoplasmosis during pregnancy 
put fetuses of infected dams at risk of congenital infection, 
with manifestations ranging from retinitis to hydrocephalus 
and cognitive impairment (3, 5, 6). However, infection with 
T. gondii before pregnancy may elicit protective immunity 
against subsequent parasite challenge, underscoring the ben-
efit of vaccination prior to pregnancy to stimulate immune 
response that protects against congenital transmission (6–8).
The worldwide distribution of T. gondii (1), the lack of human 
vaccine, the side-effects of current therapeutics (9, 10), and their 
inability to eliminate the tissue cysts, and the emergence of anti- 
T. gondii resistant strains (11) necessitate the development of new 
interventions to effectively control and prevent toxoplasmosis 
(12–14). Several vaccine strategies (e.g., inactivated, subunit, 
and DNA vaccines) against T. gondii have been described, but 
none of them was able to provide full protection. The use of live-
attenuated strain is particularly promising because it can induce 
more protective cellular and humoral immunity, simulating 
natural infection without causing the disease (12–14). Toxovax®, 
the only available commercial vaccine, is based on live-attenuated 
T. gondii S48 strain and is licensed only for use in sheep to prevent 
abortion (15).
A few attempts have been made to generate attenuated 
T. gondii strains unable to cause disease via removal of virulence 
or metabolic factors using targeted gene deletion (16). For 
instance, mitogen-activated protein kinase 1 has been shown 
to be critical for bradyzoite differentiation, attachment, and 
replication in vitro, and virulence in mice (17). Also, some dense-
granule protein (GRA2, GRA3, and GRA6) mutants have been 
shown to exhibit reduced virulence (18–20). The non-replicating 
and non-cyst-forming uracil auxotroph Δompdc mutants were 
shown to induce protective immunity against acute and chronic 
T. gondii infection in mice (21). Mic1-3KO strains lacking both 
mic1 and mic3 genes were able to induce protective immunity 
against chronic and congenital toxoplasmosis in mice, and against 
T. gondii-induced abortion in sheep (22, 23). Dense granule pro-
tein 17 (GRA17) gene has been shown to maintain the structural 
stability of the parasitophorous vacuole (PV) and mediates the 
transport of molecules across the PV membrane (24). Targeted 
deletion of ΔGRA17 reduced the ability of mutant strains to 
proliferate in  vitro or to cause disease in mice (24), indicating 
that GRA17 gene is an essential virulence factor with a potential 
immunogenicity.
In the vaccine studies presented here, we investigated the 
immunogenicity and protective efficacy of T. gondii RH ΔGRA17 
mutant strain, in the Kunming mouse model and characterized 
the protecting humoral and cellular immune responses. We 
examined the immune responses protective against not only the 
lethal infection with wild-type (wt) RH strain but also against 
heterologous local strains (PYS and TgC7) of the Chinese 
ToxoDB#9 genotype. Furthermore, the efficacy of immunization 
with ΔGRA17 mutant strain was tested against acute, latent, and 
congenital infections. Interpretation of the data and potential 
immune mechanisms involved in protection are discussed.
MaTerials anD MeThODs
ethics statement
All animal protocols were reviewed and approved by the Animal 
Administration and Ethics Committee of Lanzhou Veterinary 
Research Institute, Chinese Academy of Agricultural Sciences. 
The study was performed in strict compliance with the recom-
mendations set forth in the Animal Ethics Procedures and 
Guidelines of the People’s Republic of China. All efforts were 
made to minimize animal suffering and to reduce the numbers 
of animals used in the experiments.
Mice
Toxoplasma gondii-seronegative 8-week-old female and male 
Kunming mice were purchased from Lanzhou University 
Laboratory Animal Center, Lanzhou, China. They were housed 
under pathogen-free conditions at Lanzhou Veterinary Research 
Institute in controlled room under stable conditions (12-h/12-h 
dark/light cycle, 50–60% humidity and 22°C temperature). Mice 
had free access to sterilized food and water ad libitum. Mice were 
acclimated for 1 week before use. Kunming mice were selected 
because of their susceptibility to acute and latent infection with 
T. gondii (14). In all experiments, mice (6–10 mice per group) 
were observed daily after immunization and challenge.
Preparation of Different Parasite stages
Tachyzoites of T. gondii type I RH mutant and wt strains and 
type ToxoDB#9 −  PYS and TgC7 −  strains were maintained 
in vitro in human foreskin fibroblast (HFF, ATCC SCRC-1041) 
monolayers as previously described (25). Freshly egressed 
tachyzoites were harvested from HFF monolayers by filtra-
tion through 3-µm polycarbonate membranes and suspended 
in sterile phosphate-buffered saline (PBS). T. gondii cysts of 
type II Prugniuad (Pru) strain were maintained in Kunming 
mice by oral passage of infectious cysts in mice as described 
previously (26). The number of parasites (tachyzoites or cysts) 
of each strain was adjusted in PBS to the final number used in 
the experiments.
Preparation of soluble Toxoplasma 
antigens (sTag)
Soluble Toxoplasma antigens were prepared as previously 
described (27). Briefly, a suspension of T. gondii RH tachy-
zoites was washed in PBS and subjected to repeated freezing 
and thawing cycles and then sonicated on ice at 60 W/s. The 
preparations were centrifuged at 14,000  g for 30  min at 4°C. 
The supernatants were sterile filtered with 0.22  µm sterile 
nitrocellulose filters (Sartorius) and the STAg concentration 
was determined by the Bicinchoninic acid kit (BCA, Sigma, St. 
Louis, MO, USA), and aliquoted was stored at −80°C until use.
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generation of ΔGRA17 strain Using 
crisPr-cas9
Disruption of GRA17 gene in RH strain has been shown to 
affect the parasite’s ability to proliferate in cultured cells and its 
virulence in mice (24). We used CRISPR-Cas9 method to delete 
GRA17 gene in T. gondii RH strain as described previously 
(28, 29). Briefly, we generated a single-guide RNA (sgRNA) to 
disrupt GRA17 gene and modified pSAG1:CAS9-U6:sgUPRT 
by PCR mutagenesis using specific primers (see Table S1 in 
Supplementary Material). The DHFR* resistance cassette was 
amplified as described previously (28, 29). Then, GRA17-specific 
CRISPR-Cas9 plasmid and the DHFR* resistance cassette ampli-
cons were combined and transfected into T. gondii RH tachy-
zoites. After selection with 3 µM pyrimethamine, single clones 
were screened by PCR using specific primers (KO-GRA17-F and 
KO-GRA17-R) listed in Table S1 in Supplementary Material. 
Then, we compared the in  vitro growth of ΔGRA17 deletion 
mutant to wt T. gondii tachyzoites. Briefly, confluent monolay-
ers of HFF grown on glass coverslips positioned in the bottom 
of 6-well plates were infected with freshly purified tachyzoites 
(2 × 103/well) of mutant or wild-type (wt) strain. Coverslips were 
washed to remove extracellular parasites at 3 h after infection, 
and the parasite’s growth within the PV was assessed at 12 and 
24 h by fixation in 4% paraformaldehyde followed by imaging at 
×40 using a Leica DM IRB microscope equipped with a high-
resolution charge-coupled device camera (Nikon Japan).
immunization of Mice
Mice were immunized with 5 × 104 ΔGRA17 tachyzoites or mock-
immunized in a volume of 200  µl PBS intraperitoneally (i.p.) 
using a 26-gauge needle (Figure S1 in Supplementary Material). 
We used i.p. immunization because it can induce both mucosal 
and systemic immune responses. The type I RH strain was used 
because immunization with ΔGRA17 RH tachyzoites has been 
shown to protect mice from lethal infection (24).
immune responses in Pre-challenged 
Mice
We assessed the immune response in ΔGRA17-immunized mice 
prior to infection in order to determine the pattern of humoral 
and cellular immune responses of the vaccinated mice compared 
to non-immune control animals.
Detection of Total IgG and Antibody Isotypes in 
ΔGRA17-Immunized Mice
Blood samples were collected from the mouse tail vein at 28 and 
70 days after immunization. Serum samples were collected after 
clot retraction and were stored at –80°C until analysis. The total 
and subclasses of anti-T. gondii IgG antibodies as an indicator of 
Th1 and Th2 responses were determined by ELISA as previously 
described (30, 31). Briefly, wells of 96-well microtiter plates were 
coated with 100 µl (10 µg/ml) STAg (diluted in PBS) and were 
incubated at 4°C overnight. Each well was washed with PBS-
Tween 0.05% (PBS-T) and blocked with PBS-T plus 1% low fat 
milk for 1 h at ambient temperature. Then, the plates were washed 
three times in PBS. Then, 100 µl serum samples were added to 
the wells at a dilution of 1:25 with PBS and were incubated for 1 h 
at 37°C. The plates were washed three times with PBS, followed 
by addition of 100  µl of horseradish-peroxidase-conjugated 
goat anti-mouse IgG (1:250 diluted with PBS), anti-mouse IgG1 
(1:500 diluted with PBS), and IgG2a (1:500 diluted with PBS). 
The plate was further incubated for 1 h at 37°C. After washing 
three times, 200  µl substrate solution (1.05% citrate substrate 
buffer, 0.03% H2O2, 1.5% ABTS) was added for 20 min and the 
absorbance at 450 nm was read using ELISA plate reader (iMark 
microplate absorbance reader; Bio-Rad, Hercules, CA, USA).
Cytokine Analysis in Splenocyte Supernatants
Seventy days after immunization, mice were sacrificed and 
spleens were removed aseptically into RPMI medium in a class 
II hood and single-cell suspensions were prepared. Briefly, the 
spleen was teased gently through a tea strainer in a petri dish 
in complete RPMI medium. The resultant suspensions including 
splenocytes were harvested with a sterile Pasteur pipette allowing 
tissue debris to sediment. All separated spleen cell suspensions 
were centrifuged for 10 min at 1,200 g at 4°C, and resuspended 
in 0.3 ml of Boyle’s solution (one volume of 0.17 M tris–HCl pH 
7.65 and nine volumes of 0.16 M ammonium chloride) to lyse 
erythrocytes. After 3 min incubation, at ambient temperature, the 
spleen cells were centrifuged at 1,200 g for 5 min at 4°C, washed 
three times with RPMI, and the pellets were resuspended in 10 ml 
of complete RPMI medium. The number of viable splenocytes 
was calculated using Trypan blue exclusion assay and Neubauer 
Haematocytometer under phase contrast microscope. Dead cells 
did not exclude the dye. One million splenic cells collected from 
mice in different groups were seeded in triplicate wells in sterile 
96-well flat-bottom tissue culture plates (Corning Incorporated, 
Corning, NY, USA) in a final volume of 200 µl RPMI supplemented 
with 10% heat-inactivated fetal calf serum, 2 mM glutamine, and 
1% penicillin–streptomycin mixture. STAg or medium alone 
was added to the culture at a final concentration of 10  µg/ml. 
Culture supernatants were collected and the level of the secreted 
interleukin-2 (IL-2), IL-12, IL-10, and interferon gamma (IFN-γ) 
was determined using a commercial ELISA (eBioscience® Bender 
MedSystems GmbH, Austria).
challenge Models to Test the efficacy 
of immunization
In these experiments, the efficacy of immunization with ΔGRA17 
mutant strain was tested against acute, latent, and congenital 
infections in mice (Figure S1 in Supplementary Material).
Protection against Acute Infection
In this experiment, we investigated the immune-protection of 
ΔGRA17 tachyzoites against acute T. gondii infection. Briefly, 
70 days after immunization, mice were challenged with 1 × 103 
RH tachyzoites of T. gondii RH, ToxoDB#9 PYS, or ToxoDB#9 
TgC7 strain. ToxoDB#9 genotype is the predominant genotype in 
China and has a similar virulence to Type I RH (32). Therefore, it 
was important to determine if immune responses elicited against 
the ΔGRA17 mutant protects against challenge with the heter-
ologous local strains (PYS and TgC7) of ToxoDB#9 genotype. 
Seven days postinfection (dpi), serum and peritoneal fluid were 
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collected from ΔGRA17-immunized and RH-infected mice, non-
immunized and RH-infected mice, and non-immunized and 
uninfected mice. Then, the level of pro-inflammatory cytokines 
IFN-γ and IL-12 in the the collected sera and peritoneal washes 
was assessed by ELISA following the manufacturer’s instruc-
tions (eBioscience® Bender MedSystems GmbH, Austria). Pre-
immunization blood samples served as a control.
Protection against Chronic Infection
We also evaluated the level of protection induced by ΔGRA17 
mutant against chronic infection in mice challenged with 20 
cysts of T. gondii Pru strain. Chronically infected and immu-
nized mice and control mice were euthanized at 35  dpi and 
their brains were removed and individually homogenized in 
1  ml of PBS. The parasite cyst burden in the brain tissues of 
the mice was performed by examining dilutions of DBL-stained 
brain homogenates using a Zeiss wide-field epifluorescence 
microscope with 10× objective as previously described (33). 
Brain homogenates that did not contain cysts upon micro-
scopic examination were further bio-assayed in mice. Briefly, 
PBS-homogenized brain tissues were used to infect orally 
healthy mice (one brain homogenate per mouse). Five weeks 
later, blood samples were collected for detection of anti- 
T. gondii antibodies using ELISA as described above. Survival of 
acutely or chonically infected and immunized mice versus non-
immunized and infected mice was evaluated using Mantel–Cox 
log-rank test.
Protection against Congenital Toxoplasmosis
Seventy days post immunization female mice were mated to 
males, at two females to one male ratio, and examined every 12 h 
after copulation for evidence of a vaginal plug. The date on which 
a plug was observed was considered day 1 of pregnancy, at which 
time pregnant females were separted from male mice. Then, 
we compared between five groups of pregnant mice: (group A) 
ΔGRA17-immunized and orally gavaged with 10 tissue cysts of 
T. gondii Pru strain on day 12 of gestation, (group B) ΔGRA17-
immunized and i.p. inoculated with 200 T. gondii RH tachyzoites 
on day 18 of gestation, (group C) non-immunized, and orally 
gavaged with 10 tissue cysts of T. gondii Pru strain on day 12 of 
gestation, (group D) non-immunized and i.p. inoculated with 200 
T. gondii RH tachyzoites on day 18 of gestation, and (group E) 
non-immunized and uninfected. The level of protection against 
congenital infection was determined by analyzing litter size and 
survival rate of the naturally delivered pups at birth and 5 days 
post-delivery, and body weight (BW) at 5  days of age in i.p. 
RH-infected mice, and at birth and 35-day old in orally Pru-
infected mice. Also, the level of protection in Pru-infected mice 
was evaluated by quantifying the parasite cyst burden in the brain 
tissue in the survived pups at 35 days of age and in their dams at 
30 days after delivery. Maternal splenocytes were obtained from 
pregnant mice infected with Pru cysts on day 12 of gestation and 
were stimulated with STAg 6 days later (i.e., 18 days of gestation). 
Then, the level of IFN-γ, IL-2, IL-12 (Th1), and IL-10 (Th2) 
cytokines in immunized and infected mice, non-immunized and 
infected mice, and non-immunized and uninfected mice was 
determined as described above.
statistical analysis
All statistical analyses were performed using SPSS18.0 (SPSS Inc., 
Chicago, IL, USA). Levels of significance of the differences in 
the level of antibodies, cytokines, and parasite cyst burdens were 
compared using one-way ANOVA analysis (for comparing means 
between ≥three groups) or two-tailed, unpaired Student’s t-test 
(for comparing means between two groups). The SDs were derived 
from three independently performed experiments with three 
replicates per experiment for the in  vitro assays. Statistical sig-
nificance was set at P < 0.05. Mortality was examined by plotting 
survival curves of the different mouse groups stratified by T. gondii 
infection and immunization status using Mantel–Cox log-rank test.
resUlTs
generation of GRA17-Deficient Type i  
T. gondii
We knocked out GRA17 gene to study whether GRA17-deficient 
RH tachyzoites can be used as a live-attenuated vaccine against 
acute, chronic, and congenital toxoplasmosis in mice. CRISPR-
Cas9 system was used to delete the GRA17 coding sequence 
(Figure  1A). The sgRNA and DHFR* marker were inserted 
into the GRA17 coding sequence and stable, single clones 
were successfully generated and validated by PCR (Figure 1B). 
We observed a significant defect in the appearance of the PV, 
along with less intra-vacuolar tachyzoite’s proliferation in 
the ΔGRA17 mutant compared to the wt strain (Figure  2). 
Gray-level histogram analysis showed that the PV produced 
by wild T. gondii RH strain had a significantly larger fraction 
of darker pixels, which represent the large number of growing 
intra-vacuolar parasites, whereas a significantly lower number 
of parasites was observed in the PV produced by the ΔGRA17 
mutant strain, as shown by a greater proportion of the lighter 
pixels (Figure 3).
immune responses of Mice to 
immunization
The prechallenge sera from the immunized mice were monitored 
for their IgG subclasses and for Th1 and Th2 cytokine profiles. 
The presence of specific anti-T. gondii IgG antibodies at 28 and 
70  days after immunization was determined by quantitative 
ELISA. At day 28 postimmunization, all immunized mice had 
seroconverted with a higher level of IgG antibodies compared 
with naïve mice (Figure 4). Next, we tested whether a Th1 and/
or Th2 response was elicited in the immunized mice by evaluat-
ing the levels of specific antibodies, IgG1 and IgG2a. At 28 days 
postimmunization, the levels of IgG2a in immunized mice were 
significantly higher compared to control naïve mice. In contrast, 
levels of IgG1 did not increase in immunized mice compared 
with naïve mice (Figure 4). At 70 days postimmunization, the 
levels of IgG1 in immunized mice increased, and the levels 
of IgG and IgG2a remained higher compared to naïve mice 
(Figure 4). Cytokines released from spleen cells after stimula-
tion with STAg were evaluated by ELISA. As shown in Figure 5, 
the levels of Th1-type cytokines (IFN-γ, IL-2, and IL-12) in 
ΔGRA17-immunized mice were significantly higher than that in 
FigUre 2 | Phenotypic analysis of ΔGRA17-infected human foreskin 
fibroblast cells. ΔGRA17 mutant developed deformed parasitophorous 
vacuoles with limited parasite proliferation capability (white arrows) compared 
to the normal intra-vacuolar tachyzoite’s growth and vacuole’s morphology 
exhibited by the wt strain (black arrow), indicating the successful deletion of 
the GRA17 gene. Scale bars, 10 µm.
FigUre 1 | CRISPR/Cas9-mediated disruption of GRA17 gene in Toxoplasma gondii Type I RH strain. (a) Schematic representation of CRISPR-Cas9-mediated 
disruption of GRA17 gene by insertion of pyrimethamine-resistant DHFR* cassette into GRA17. Transfection of pSAG1:CAS9-U6:sgGRA17 together with the DHFR* 
amplicon was used to disrupt the GRA17 coding region. (B) KO forward and KO reverse primers were used to amplify the small fragment. Diagnostic PCR showing 
DHFR* cassette integration in a representative GRA17:DHFR* clone compared with the parental wild-type RH strain (wt). M indicates the molecular weight marker.
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naïve mice. In the interim, the level of Th2-type cytokine (IL-10) 
was significantly increased in supernatants from spleen cells of 
ΔGRA17-immunized mice compared to naïve mice.
Protection against acute infection
Kunming mice, 70 days post ΔGRA17 immunization, were chal-
lenged with 1 × 103 tachyzoites of T. gondii RH, PYS, or TgC7 
strain. All immunized mice survived the challenge with the 
three strains. By contrast, all naïve mice challenged with RH, 
PYS, or TgC7 strain died within 10 dpi (Figure 6). Assessment 
of cytokine response after chgallenge with with RH was per-
formed 7  dpi using ELISA. Analysis was performed on serum 
and peritoneal fluids from ΔGRA17-immunized and infected 
mice, non-immunized and infected mice, and non-immunized 
and uninfected mice. The levels of IFN-γ and IL-12 in the sera 
and peritoneal washes (Figure  7) were significantly higher in 
non-immunized and infected mice than in the immunized and 
infected, and non-immunized and uninfected mice.
Protection against chronic infection
Seventy days after immunization, both immunized and control 
mice were orally gavaged with 20 cysts of T. gondii Pru strain. 
All ΔGRA17-immunized and Pru-infected mice survived 
compared to only 40% survival of non-immunized and infected 
mice (Figure  8A). Parasite cyst burden in the brains 5 weeks 
post-challenge with T. gondii Pru cysts was determined. Infected 
mice had a larger number of cysts (4,296 ±  687 cysts/brain) 
compared with immunized mice that had significantly less cyst 
burden (53 ± 15 cysts/brain) (P < 0.05). Brain cysts were not 
found in 4 out of 10 (40%) immunized mice by microscopic 
examination (Figure  8B). Brain tissues of these four immu-
nized mice that did not show any cysts were homogenized and 
bio-assayed in naïve mice. Anti-T. gondii IgG antibodies were 
found in two of these four naïve mice suggesting that two brain 
homogenates derived from immunized and infected mice are 
infected based on serological evidence and two were completely 
free of parasites as evidence by negative microscopic and sero-
logical results.
Protection against congenital 
Toxoplasmosis
Immunization with ΔGRA17 was well tolerated during preg-
nancy as evidenced by the absence of abortion in immunized 
mice, number of pups per litter, survival rate, and BW of pups 
born to immunized dams. Also, it is important to note that an 
immunopathologic response was not induced by immunization 
with ΔGRA17 strain.
Protection against Type I RH Strain Infection during 
Pregnancy
Female mice were mated with males on day 70 after immuniza-
tion and pregnant mice were infected with 200 RH tachyzoites 
FigUre 3 | Gray-level histogram for mutant and wild-type Toxoplasma gondii strains. (a,B) show the number of pixels in each gray level (0–256) of the images of the 
parasitophorous vacuole (PV) with 0 signifying black and 256 signifying white. (c,D) show the cumulative pixel count for the same images, which are shown in (e,F). 
This shows that PV produced by wild-type strain had a significantly larger fraction of darker pixels, which represents the large number of the growing intra-vacuolar 
parasites, whereas the PV of mutant strain had significantly lower quantity of the intra-vacuolar parasites, as shown by a greater proportion of the ligher pixels.
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on day 18 of gestation, 3  days before neonates were born. 
Neonates were counted at birth and visually inspected for 
appearance and sizes. The mean sizes of viable neonates born 
to immunized and infected mice were similar to pups born to 
non-immunized and uninfected mice and in both groups, no 
abortions were observed. In contrast, the mean litter sizes of 
viable neonates born to non-immunized and infected mice were 
significantly reduced compared to pups from immunized and 
infected mice, and abortions were also observed (Figure  9A). 
Five days after birth, the survival rate and mean BW of pups 
born to non-immunized and uninfected, and immunized and 
infected mice were significantly higher than that from non-
immunized and infected mice (Figure  9B). Non-immunized 
and infected dams showed clinical signs of toxoplasmosis, such 
as weight loss, weakness, anorexia, hunched posture, and ruffled 
fur, which became profound by day 7 after challenge. In contrast, 
immunized and infected, and non-immunized and uninfected 
dams did not show any clinical signs (i.e., exhibited normal 
physical conditions). Some non-immunized and infected dams 
that were unable to eat and drink were sacrificed (and their pups) 
on day 5 after birth to detect the parasites DNA in their spleen 
and livers. T. gondii DNA was found in all non-immunized and 
infected dams, but not in any of the 10 examined pups. However, 
parasites DNA was detected in some aborted fetuses. The pups 
from the immunized and infected mice had equivalent mean BW 
and survival rate to that from non-immunized and uninfected 
dams on day 35 of age (date not shown).
Protection against Type 2 Pru Strain Infection during 
Pregnancy
Pregnant dams were infected orally with 10 cysts of T. gondii 
Pru strain on day 12 of gestation. After birth, litter size, survival 
rate, and BW of pups were determined. As shown in Figure 10A, 
the number of neonates per litter from immunized and infected 
mice was significantly higher than that of non-immunized and 
infected mice (P <  0.05), although no significant difference in 
the litter sizes, and survival rate and BW of pups (35 days after 
birth) was observed between immunized and infected mice, and 
non-immunized and uninfected mice. In contrast, survival rate 
and BW of pups from non-immunized and infected mice were 
significantly lower than that of non-immunized and uninfected, 
and immunized and infected mice (Figure 10B). One month and 
35 days after birth, dams and their pups were euthanized, respec-
tively, and the number of cysts in their brain tissue was assessed. 
The tissue cysts were found in all pups born to non-immunized 
and infected dams, whereas cysts were detected in only 48.2% of 
FigUre 5 | Levels of Th1 [IFN-γ, interleukin-2 (IL-2), and IL-12] and Th2 (IL-10) cytokines produced by spleen cells of ΔGRA17-immunized mice. Spleen cells from 
mice were obtained 70 days postimmunization and were stimulated in vitro with soluble Toxoplasma gondii tachyzoite antigen (10 µg/ml). Cell-free supernatants 
were harvested and evaluated for IL-2, IL-10, IL-12, and INF-γ using ELISA. Significance compared with naïve control mice: ***p < 0.001.
FigUre 4 | Humoral response and antibody isotype profile in serum of mice immunized with ΔGRA17 by intraperitoneal route. Levels of IgG and IgG subclass (IgG1 
and IgG2a) antibodies in the sera of mice at 28 and 70 days after ΔGRA17-immunization compared to naïve mice. The patterns of IgG2a to IgG1 at 28 and 70 days 
postimmunization suggest the induction of a Th1 immune response at 28 days postimmunization, which remained high and the induction of Th2 immune response 
at day 70 postimmunization. Results are expressed as mean of OD450 ± SD. Significance compared with naïve control mice: ***p < 0.001.
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pups born to immunized and infected dams. The average num-
ber of brain tissue cysts in pups from immunized and infected 
mice were significantly lower than that of non-immunized and 
infected dams (56 ± 25 cysts/brain, n = 27 vs. 919 ± 339 cysts/
brain, n  =  19; P  <  0.001). Also, ΔGRA17-immunized dams 
displayed significantly lower parasite burdens in the brain than 
non-immunized mice (Figure  11). Stimulation of maternal 
splenocytes with T. gondii antigen, 18 days of gestation (pregnant 
mice were infected with Pru cysts on day 12 of gestation), resulted 
in the production of higher amounts of T. gondii-specific IFN-γ, 
IL-2, IL-12 (Th1), and IL-10 (Th2) cytokines in immunized and 
infected mice compared with non-immunized and infected mice 
or non-immunized and uninfected mice (P < 0.001; Figure 12). 
However, there was no significant difference in levels of these 
cytokines between non-immunized and infected mice, and 
non-immunized and uninfected mice (P > 0.05). It remains to be 
FigUre 7 | Pro-inflammatory cytokines produced by ΔGRA17-immunized mice after challenge with Toxoplasma gondii RH. Mice were challenged with 1 × 103 
RH tachyzoites 70 days postimmunization and the levels of IFN-γ and IL-12 in the serum and peritoneal washes were assessed by ELISA at 7 days 
postinfection. Highest levels of pro-inflammatory cytokines were found in the non-immunized and infected mice. Significance compared with naïve control mice: 
***p < 0.001.
FigUre 6 | Protection of mice against acute lethal Toxoplasma gondii infection. Survival curves of ΔGRA17-immunized mice, challenged intraperitoneally  
with 1 × 103 tachyzoites of RH, PYS, or TgC7 strain 70 days after immunization. The survival of mice was monitored for 35 days. A Log-rank (Mantel–Cox) test 
revealed that the difference in the survival rates between immunized and infected groups compared to non-immunized and infected groups as P = 0.003. All 
mice in the immunized groups remained alive at day 35 after infection, but all mice in the infected and non-immunized groups died between day 7 and 10 after 
infection. In addition to separate curves that show the difference in the survival rate between immunized and non-immunized mouse groups infected with RH,  
PYS, or TgC7 strain (a–c), the overall survival rates in all immunized groups compared with the non-immunized positive control groups were combined  
in one graph (D).
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FigUre 8 | Immunization with ΔGRA17 promotes survival and inhibits brain cyst burden after infection. (a) Survival curves following challenge of ΔGRA17-
immunized mice with 20 cysts of Toxoplasma gondii type II Pru strain, compared with mock-immunized mice, 70 days after immunization.  
The survival of mice was monitored for 35 days. A Log-rank (Mantel–Cox) test demonstrated a significant difference between the immunized and control groups 
(P = 0.0001). (B) Cyst burden in the brain of mice that survived to 35 days after challenge (ΔGRA17-immunized mice vs infected, non-immunized mice). Data points 
indicate means ± SD.
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elucidated why infection with Pru strain at 12 days of gestation 
failed to elicit more cytokines than control, uninfected, mice.
DiscUssiOn
Here, we utilized CRISPR-Cas9 method to generate ΔGRA17 
mutants, which had a phenotype similar to that reported 
previously (24). Next, we investigated the potential of 
immunization with GRA17-defective mutants of T. gondii RH 
strain, as a live-attenuated vaccine, to protect Kunming mice 
against acute, chronic, and congenital forms of toxoplasmosis. 
We also quantified the levels of antibodies and cytokines 
evoked in mice against challenge with ΔGRA17 mutant using 
ELISA. The pattern of the immune response observed in 
immunized mice suggested a sequential Th1 and Th2 T  cell 
response, reflecting the activation of both cell- and antibody-
mediated responses.
immune correlates of Protection
A major goal of vaccine development is the induction of adequate 
immune responses against antigens delivered by the mucosal 
route. ΔGRA17-immunized mice developed a high level of anti-
T. gondii IgG at 28 and 70 days after immunization. This level of 
antibodies plays important role in protection against subsequent 
FigUre 10 | Protection of mice against type II Pru cysts infection on day 12 of gestation. (a) The litter size of pups from the non-immunized and uninfected mice 
(naïve), non-immunized and Pru-infected mice, and immunized and Pru-infected mice was assessed at birth and 35 days after birth. (B) The body weighs of 
35 days old pups. Data points indicate means ± SD. Significance compared with naïve control mice: **p < 0.01, ***p < 0.001.
FigUre 9 | Protection of mice against type I RH tachyzoite infection on day 18 of gestation. (a) The litter size of pups from the non-immunized and uninfected mice 
(naïve); non-immunized and RH-infected mice, and immunized and RH-infected mice was assessed at birth and 5 days after birth. (B) The body weight of 5-day-old 
pups. Significance compared with naïve control mice: **p < 0.01, ***p < 0.001.
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infection with T. gondii tachyzoites and in controlling T. gondii 
during the chronic phase of infection by preventing cysts’ reacti-
vation (34). We next analyzed the antibody types elicited against 
immunization with ΔGRA17 mutant by studying the antibody 
subclasses (IgG1 and IgG2a). Our results showed that immu-
nization with live-attenuated ΔGRA17 strain promoted both 
cell- (Th1) and humoral- (Th2) mediated immune responses 
in Kunming mice. Immunized mice exhibited IgG2a as the 
predominant antibody’s class during early infection followed by 
upregulation of IgG1 in the chronic phase, probably as a result 
of Th1 to Th2 switching. A high ratio of IgG2a to IgG1 antibody 
titers observed at 28  days after immunization indicated that 
Th1 immune response was induced. However, at 70 days after 
immunization the level of IgG1 antibody increased, suggesting 
the induction of a mixed Th1/Th2 immune response. These 
results demonstrated a sequential upregulation of antiparasite 
IgG2a and IgGl antibodies. This isotypes’ pattern is supported 
by the patterns of cytokines detected in the supernatants from 
spleen cell cultures where the levels of Th1-type cytokines 
(IFN-γ, IL-2, and IL-12) and Th2-type cytokine (IL-10) in 
ΔGRA17-immunized mice were significantly higher compared 
to naïve mice. The fact that IgG2a is known to be elicited by 
IFN-γ in mice (35) is consistent with our finding where a bias 
to Th1 response (i.e., higher IgG2a/IgG1) was correlated with 
early IFN-γ production, pointing to the important role of IFN-
γ in eliciting high IgG2a responses against avirulent T. gondii, 
therefore, influencing the immunogenicity of this vaccine.
Protection against acute and chronic 
Toxoplasmosis
High levels of Th1-type cytokines including IFN-γ, IL-2, and 
IL-12 developed in immunized mice might have provided 
immune-protection to mice against challenge with a lethal 
dose of wt strains (type I RH or two ToxoDB#9 strains). Deaths 
FigUre 11 | Immunization decreases the parasite tissue cyst burden in infected 
dams. Female mice were immunized with ΔGRA17 and 70 days after they were 
mated and gavaged orally with 10 Pru cysts on day 12 of gestation. At 30 days 
after delivery, the cysts loads in brain tissue were analyzed. Non-immunized 
dams showed higher tissue burdens of cysts than immunized mice. Data points 
indicate means ± SD. Significance compared with infected mice: ***p < 0.001.
FigUre 12 | Production of Toxoplasma gondii-specific Th1 and Th2 cytokines in GRA17-immunized mice after infection with Pru cysts on day 12 of gestation. 
Immunized, pregnant mice were infected with T. gondii Pru cysts 12 days of gestation and spleen cells were collected 6 days after infection. Splenocyte culture was 
stimulated in vitro with T. gondii soluble tachyzoite antigen (10 µg/ml). Cell-free supernatants were harvested and evaluated for interleukin-2 (IL-2), IL-10, IL-12, and 
INF-γ. Cytokine concentrations represent mean ± SD after subtraction of background control values with medium only. Significance compared with uninfected and 
non-immunized (naïve) mice: ***p < 0.001.
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occurred by days 7–10, with 100% mortality in non-immunized 
and infected mice, whereas all immunized mice survived. Seven 
days following a subsequent challenge with T. gondii RH strain 
a significantly higher (P < 0.001) level of IFN-γ and IL-12 was 
detected in the peritoneal washes and sera of non-immunized 
and infected mice compared to ΔGRA17-immunized and 
infected mice. This finding suggests that the response of the 
naïve and infected mice was of an inflammatory nature and 
that ΔGRA17-immunized and infected mice developed a 
balanced pro-(Th1) and anti-inflammatory (Th2) cytokine 
response. The remarkably high levels of IFN-γ and IL-12 and 
the associated over-inflammation are probably the basis for 
adverse health complications developed in naïve and infected 
mice as previously reported (36, 37). T. gondii infection is known 
to induce a Th1-biased inflammatory response by stimulating 
T  cells, macrophages, natural killer cells, dendritic cells, and 
neutrophils to produce IFN-γ and IL-12 (38–41). These two 
cytokines are central to the development of immunity against 
T. gondii infection. Suppression of IL-2 by effector T cells trig-
gered by T. gondii infection can cause Treg cells to lose their 
capacity to balance Th1 immune responses, eventually leads 
to immunopathogenesis and the death of mice during acute 
T. gondii infection (42). On the other hand, the Th2 cytokine 
IL-10 is essential for counterbalancing the exacerbated inflam-
matory Th1 response that induces immunopathologies (36). 
Therefore, the balanced level of Th1/Th2 cytokines observed in 
ΔGRA17-immunized and infected mice was adequate to control 
the dissemination of tachyzoites, but not excessive enough to 
elicit significant inflammation. The immune response triggered 
by ΔGRA17 immunization also fully protected mice against oral 
12
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infection with type II Pru cysts. Our results showed that only 
40% non-immunized mice and orally infected 20 Pru cysts sur-
vived, whereas all immunized mice (100%) survived. It is worth 
mentioning that although the number of cysts in immunized 
mice was significantly reduced, immunization did not prevent 
the establishment of chronic infection and cyst formation in 
80% of the immunized mice.
impact on congenital Toxoplasmosis
We assessed the protection conferred by immunization 
against transplacental transmission and results showed that 
immunized mice infected with 200 tachyzoites of T. gondii RH 
strain on day 18 of gestation did not show any significant dif-
ferences in the litter size, survival rate, or mean BW of pups at 
day 5 after birth compared to pups from non-immunized and 
uninfected mice. Also, immunization protected completely 
the dams form developing clinical signs of toxoplasmosis. In 
contrast, non-immunized and infected dams developed clini-
cal disease and aborted. Furthermore, the litter size, survival 
rate, and mean BW of their pups were significantly reduced. 
The small litter size and low survival rate of pups born to 
non-immunized dams can be attributed to T. gondii infection 
because parasite DNA was detected in the aborted fetuses. The 
reduced BWs of pups may be caused by the limited care and 
postnatal malnutrition as a consequence of infection of the 
dams.
Likewise, in the immunized pregnant mice orally gavaged 
with Pru cysts on day 12 of gestation the litter size, survival rate 
and mean BW of the pups at day 35 after birth were not different 
from that of non-immunized and uninfected mice. In contrast, 
the litter size, survival rate, and mean BW of pups from non-
immunized and Pru-infected mice were significantly reduced 
(P < 0.05). It can be argued that vaccination in pregnant mice 
with a live-attenuated parasite strain may be fraught with the 
possibility of transmission of infection to the fetus. However, 
although the immune responses triggered by ΔGRA17 immu-
nization did not completely block the vertical transmission, a 
significantly less tissue cyst burden was observed in the brain 
of pups from immunized and Pru-infected mice. As expected, 
all pups of mock-immunized and Pru-infected dams had more 
brain cysts. With regard to the brain tissue cyst load in infected 
dams, there was a significantly larger number of brain cysts in 
non-immunized than immunized dams. These results indicate 
that immunization with ΔGRA17 can induce a partial protec-
tive immunity against subsequent i.p. infection with T. gondii 
tachyzoites RH strain during the third trimester of gestation 
and oral infection with Pru cysts during the second trimester 
of gestation.
Further analysis of the cytokines secreted by maternal spleen 
cells of immunized dams revealed higher levels of Th1-type 
cytokines (IFN-γ, IL-12, and IL-2) and Th2 cytokine (IL-10) 
in immunized and Pru-infected compared to non-immunized 
and infected mice, and non-immunized and uninfected mice. 
This cytokines’ pattern in immunized and infected mice is 
similar to that observed at 70 days after immunization in non-
pregnant mice. But, T. gondii is known to stimulate a strong 
Th1 response characterized by the early classical activation 
of macrophages and the production of pro-inflammatory 
mediators, such as IL-12, IFN-γ, and nitric oxide. Th1 response 
can suppress the development of alternative activation of 
macrophages and, thus, Th2 responses. Thus, while high level 
of anti-T. gondii Th1 immune response is required to control 
the materno–fetal transmission of T. gondii (43) and prevent 
congenital transmission (44, 45), it can adversely affect the 
pregnancy (37).
The increased IL-10 level in our study is interesting because 
this cytokine plays a critical role in downregulating IFN-γ 
responses in C57BL/6 mice following T. gondii infection. 
IL-10-deficient C57BL/6 mice displayed elevated IL-12 levels 
and consequently increased IFN-γ and TNF-α responses, which 
resulted in hepatic inflammation and necrosis (36). Previous 
work showed a higher rate of materno–fetal transmission of 
T. gondii in IFN-γ-deficient C57BL/6 mice compared to wt 
C57BL/6 mice (43). On the other hand, the pregnancy outcome 
of C57BL/6 mice infected with T. gondii improved by treatment 
with recombinant IL-10 and deteriorated in IL-10-deficient mice 
compared to T. gondii-infected naïve mice (46). Increased level 
of the Th2-type cytokine, IL-10, restrains Th1 immune response 
and Th1-mediated immunopathology, while maintaining a Th2 
immune response (47, 48).
During pregnancy, the maternal immune response is shifted 
toward a Th2 cytokine profile in order to accommodate the 
growing fetus and to ensure maintenance of the pregnancy. 
Therefore, while the high level of Th1-type cytokines in the 
immunized mother plays an important role in countering 
congenital transmission (44, 45), Th2-type cytokine IL-10 is 
needed to balance Th1 immune response in order to maintain 
the pregnancy. In agreemnt with these findings, we observed 
that pregnancy was not successful in mice mated 1 month after 
immunization where Th1 response was dominating. The role 
of IL-10 in preventing immunopathology during toxoplasmo-
sis is a topic of great interest. CD4+ T lymphocyte cells derived 
from mice infected with T. gondii-irradiated tachyzoites were 
found to co-produce IFN-γ and IL-10 (49). Also, IL-10 pro-
duction was found to require a “reactivation” step involving 
IL-12 production and subsequent IFN-γ production by CD4 
T cells (50). Therefore, simultaneous production of antagonis-
tic IL-10 and IFN-γ cytokines by CD4 Th1 cells in response to 
T. gondii suggests that conditions that maintain anti-T. gondii 
Th1 immunity also promote a negative feedback mechanism 
for limiting Th1 hypersensitivity and inflammatory tissue 
damage.
cOnclUsiOn
Our study shows the feasibility of using live attenuated ΔGRA17 
mutant RH strain of T. gondii for vaccination against T. gondii 
infection. Our results also indicate that i.p. immunization of 
Kunming mice with ΔGRA17 mutant RH strain can generate 
an immune response protective against T. gondii infection and 
disease at a distant site of challenge. Partial protection was 
achieved against challenge with homologous and heterologous 
strains of the same and different genotypes. This effect was 
demonstrated by an improvement in the survival rate and a 
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reduction in the parasite cyst burden in the brain of immunized 
mice. ΔGRA17-immunized mice developed a sequential Th1 
and Th2 response as indicated by high levels of Th1 immunity 
(IFN-γ, IL-2, IL-12, and IgG2a) at 28 day postimmunization and 
the elevation of Th2 protective immunity (IL-10 and IgG 1) levels 
at 70 days postimmunization compared to naïve controls. Partial 
protection against congenital transmission was demonstrated by 
significant reduction in the cyst burden in the brain of pups and 
their dams, and improvement in the survival rate and BW of 
pups born to immunized dams compared to non-immunized 
dams. Given the potential efficacy of ΔGRA17 mutant vaccine, 
the data generated in mice should be extended to higher animal 
models.
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TaBle s1 | Details of single guide RNA and identification primers used in this 
study.
FigUre s1 | Schematic illustration of the study design. Experimental overview 
of the present investigation from immunization of Kunming mice with 5 × 104 
ΔGRA17 tachyzoites (a), assessment of immune responses in the serum of 
immunized mice prior to infection (B) to the evaluation of the efiicacy of the 
immunization against acute infection (c), chronic infection (D), and congenital 
infection (e). For simplicity in this illustration, only the experiments that involved 
the immunized and infected groups are shown. More details about other 
experimental mouse groups and controls can be found in “Materials and 
Methods.” Abbreviations: i.p., intraperitoneal; dpi, days post infection.
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